ATE263247T1 - Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate - Google Patents
Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugateInfo
- Publication number
- ATE263247T1 ATE263247T1 AT98100603T AT98100603T ATE263247T1 AT E263247 T1 ATE263247 T1 AT E263247T1 AT 98100603 T AT98100603 T AT 98100603T AT 98100603 T AT98100603 T AT 98100603T AT E263247 T1 ATE263247 T1 AT E263247T1
- Authority
- AT
- Austria
- Prior art keywords
- pep
- joined
- peptide
- fusion protein
- image
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 1
- 102000055277 human IL2 Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2219961A CA2219961C (en) | 1998-01-09 | 1998-01-09 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
| AU51821/98A AU5182198A (en) | 1998-01-09 | 1998-01-12 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
| EP98100603A EP0931836B1 (de) | 1998-01-09 | 1998-01-15 | Peptid aus humanem Interleukin-2 zur Steigerung der Vasopermeabilität und dessen Immunkonjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE263247T1 true ATE263247T1 (de) | 2004-04-15 |
Family
ID=31720801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98100603T ATE263247T1 (de) | 1998-01-09 | 1998-01-15 | Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0931836B1 (de) |
| AT (1) | ATE263247T1 (de) |
| AU (1) | AU5182198A (de) |
| CA (1) | CA2219961C (de) |
| DE (1) | DE69822779T2 (de) |
| ES (1) | ES2218717T3 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| WO2019058263A1 (en) * | 2017-09-19 | 2019-03-28 | Auckland Uniservices Limited | PEPTIDES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF ADIPONECTIN |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636463A (en) * | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
| IL91933A (en) * | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
| JPH0720991B2 (ja) * | 1989-02-08 | 1995-03-08 | 株式会社クラレ | 新規なペプチドおよびその用途 |
-
1998
- 1998-01-09 CA CA2219961A patent/CA2219961C/en not_active Expired - Fee Related
- 1998-01-12 AU AU51821/98A patent/AU5182198A/en not_active Abandoned
- 1998-01-15 AT AT98100603T patent/ATE263247T1/de not_active IP Right Cessation
- 1998-01-15 EP EP98100603A patent/EP0931836B1/de not_active Expired - Lifetime
- 1998-01-15 DE DE69822779T patent/DE69822779T2/de not_active Expired - Fee Related
- 1998-01-15 ES ES98100603T patent/ES2218717T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2218717T3 (es) | 2004-11-16 |
| HK1023788A1 (en) | 2000-09-22 |
| AU5182198A (en) | 1999-07-29 |
| EP0931836A1 (de) | 1999-07-28 |
| CA2219961A1 (en) | 1999-07-09 |
| EP0931836B1 (de) | 2004-03-31 |
| DE69822779D1 (de) | 2004-05-06 |
| DE69822779T2 (de) | 2005-03-10 |
| CA2219961C (en) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69807679D1 (de) | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren | |
| MA27544A1 (fr) | Conjugues de l'hormone de croissance humaine chimiquement modifies. | |
| JP2019163319A5 (de) | ||
| DK1347730T3 (da) | Rekombinante anti-CD30-antistoffer og anvendelser deraf | |
| ATE373712T1 (de) | Natürlicher menschlicher antikörper | |
| FI911319A0 (fi) | Polypeptidderivat. | |
| EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
| DK1642972T3 (da) | Terapeutisk anvendelse af BR43X2 opløselige receptorer | |
| DK97987A (da) | Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation | |
| MXPA05007843A (es) | Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes. | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| ES2134212T3 (es) | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. | |
| GEP20084484B (en) | Antibodies to insulin-like growth factor i receptor | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| IL171779A (en) | Immunoconjugates comprising an immunoglobulin constant region and a biologically active molecule | |
| ATE444969T1 (de) | Dimerisiertes peptid | |
| RU2017101662A (ru) | Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения | |
| JP2004518624A5 (de) | ||
| ES2228903T3 (es) | Pegilacion de ligandos que mejora la actividad antitumoral y reduce la toxicidad de inmunoconjugados. | |
| ATE263247T1 (de) | Peptid aus humanem interleukin-2 zur steigerung der vasopermeabilität und dessen immunkonjugate | |
| NO20033718L (no) | Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus | |
| RU2020137092A (ru) | Скрининг участков присоединения с фиксированной точкой в конъюгате цистеин-модифицированное антитело-токсин (tdc) | |
| UA88604C2 (ru) | Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания | |
| RU2350351C2 (ru) | Композиции и лекарственные формы на основе гастрина, методы применения и получения | |
| ES2114527T3 (es) | Anticuerpos que reconocen especificamente la proteina de enlace de la somatotropina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0931836 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |